Romosozumab + Alendronate (Fosamax) + Placebo Romosozumab + Placebo Alendronate
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteoporosis, Post-menopausal
Conditions
Osteoporosis, Post-menopausal
Trial Timeline
Mar 20, 2026 → Jun 1, 2027
NCT ID
NCT06973109About Romosozumab + Alendronate (Fosamax) + Placebo Romosozumab + Placebo Alendronate
Romosozumab + Alendronate (Fosamax) + Placebo Romosozumab + Placebo Alendronate is a phase 2 stage product being developed by Amgen for Osteoporosis, Post-menopausal. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06973109. Target conditions include Osteoporosis, Post-menopausal.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06973109 | Phase 2 | Recruiting |
Competing Products
20 competing products in Osteoporosis, Post-menopausal